SiLO TFX
Commercial- Indications
- Sacroiliac joint fusion
Company intelligence / Profile preview
Aurora Spine has commercialized a portfolio of minimally invasive spinal implants, including the ZIP™ Interspinous Fixation device. The company recently completed enrollment in the REFINE study, a prospective multi-center trial evaluating safety and efficacy for lumbar interlaminar fusion. Results are expected to provide robust evidence for improved patient outcomes in degenerative disc disease.
The company anticipates FDA approval for its facet system, which would expand its offerings into an estimated $3.8 billion market.
Revenue has reached approximately $15.6 million annually with quarterly revenues between $4.8–$5 million as of late 2024.
Aurora’s SiLO-TFX kit deployment and sales force expansion are driving growth in pain management markets.
Clinical data from the REFINE study will be presented at ASPN July 2025.
Overall, Aurora’s devices are designed to bridge conservative care and more invasive surgery with less traumatic options.
3 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Aurora Spine and Pain.